Boston Scientific
Medical device giant whose TheraSphere glass microspheres deliver yttrium-90 radioembolisation in liver cancer.
Overview
Boston Scientific, based in Marlborough, Massachusetts, and listed as BSX, is the medical device company whose TheraSphere glass microspheres deliver yttrium-90 radioembolisation in liver cancer. TheraSphere has held FDA approval for hepatocellular carcinoma since 2021, was studied in the EPOCH trial in colorectal liver metastases, which was positive for progression-free survival, and is being tested in combination with immunotherapy, and the company also sells drug-eluting embolic beads and other interventional oncology devices. Nuclide links it to hepatocellular carcinoma and colorectal cancer and to the radioembolisation and transarterial chemoembolisation technology records. Whether device-based liver-directed therapy keeps its role as systemic options improve is the open question. The technology pages carry the trial detail.
Scorecard
All companies- approved products +6
- modalities +2
- regions +1
- registry trials +10
Microscopic glass beads containing a radioactive metal are injected into the artery that supplies a liver tumour. The beads stay in place permanently and give off radiation that fades away within about two weeks.
Similar pages
not linked directly; found by shared links- CompanySirtex Medical
Shares Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma, Quirem Medical, Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma.
- AgentHolmium-166 microspheres
Shares Yttrium-90 glass microspheres, Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma, Yttrium-90.
- IsotopeHolmium-166
Shares Quirem Medical, Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma, Yttrium-90.
- TermTARE / SIRT (radioembolisation with yttrium-90)
Shares Quirem Medical, Hepatocellular carcinoma, Yttrium-90.
- AgentYttrium-90 resin microspheres
Shares Yttrium-90 glass microspheres, Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma, Yttrium-90.
- AgentDurvalumab
Shares TheraSphere With Durvalumab and Tremelimumab for HCC, Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma, Hepatocellular carcinoma.
- IndicationIntermediate hepatocellular carcinoma (BCLC B)
Shares Quirem Medical, Radioembolisation (TARE / SIRT, yttrium-90), Hepatocellular carcinoma, Yttrium-90.
- TrialA US Study to Evaluate Transarterial Radioembolization (TARE) in Combination With Durvalumab and Bevacizumab Therapy in People With Unresectable Hepat
Shares Radioembolisation (TARE) with durvalumab in hepatocellular carcinoma, Hepatocellular carcinoma, Yttrium-90.